Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.

Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R.

FASEB J. 2010 Jun;24(6):2040-55. doi: 10.1096/fj.09-138305. Epub 2010 Feb 12.

2.

IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Ning Y, Riggins RB, Mulla JE, Chung H, Zwart A, Clarke R.

Mol Cancer Ther. 2010 May;9(5):1274-85. doi: 10.1158/1535-7163.MCT-09-1169.

3.

Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol.

Ye X, Yuan L, Zhang L, Zhao J, Zhang CM, Deng HY.

Asian Pac J Cancer Prev. 2014;15(12):5001-7.

4.

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.

Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ.

Breast Cancer Res. 2010;12(3):R32. doi: 10.1186/bcr2586. Epub 2010 Jun 4.

5.

Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.

Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS.

Mol Cancer Ther. 2015 Nov;14(11):2411-21. doi: 10.1158/1535-7163.MCT-14-0689. Epub 2015 Sep 2.

6.

Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.

Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.

Breast Cancer Res. 2008;10(6):R104. doi: 10.1186/bcr2208. Epub 2008 Dec 5.

7.

Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.

Crawford AC, Riggins RB, Shajahan AN, Zwart A, Clarke R.

PLoS One. 2010 Jan 6;5(1):e8604. doi: 10.1371/journal.pone.0008604.

9.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.

Endocr Relat Cancer. 2006 Dec;13(4):1121-33.

10.

Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.

Cook KL, Wärri A, Soto-Pantoja DR, Clarke PA, Cruz MI, Zwart A, Clarke R.

Clin Cancer Res. 2014 Jun 15;20(12):3222-32. doi: 10.1158/1078-0432.CCR-13-3227. Erratum in: Clin Cancer Res. 2016 Jun 1;22(11):2825.

11.

Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.

Yamaguchi N, Nakayama Y, Yamaguchi N.

J Biol Chem. 2017 May 19;292(20):8136-8148. doi: 10.1074/jbc.M116.763276. Epub 2017 Mar 7.

12.

Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB.

Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A, Fernandez-Salguero PM.

Int J Cancer. 2005 May 20;115(1):74-84. Erratum in: Int J Cancer. 2005 Oct 10;116(6):1004. Salguero, Pedro M Fernandez [corrected to Fernandez-Salguero, Pedro M].

13.

Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression.

Wang Y, Wang X, Zhao H, Liang B, Du Q.

J Chemother. 2012 Dec;24(6):348-57. doi: 10.1179/1973947812Y.0000000049.

PMID:
23174100
14.
15.

A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.

Ma Y, Preet A, Tomita Y, De Oliveira E, Zhang L, Ueda Y, Clarke R, Brown M, Rosen EM.

Oncotarget. 2015 Dec 1;6(38):40388-404. doi: 10.18632/oncotarget.6323.

16.

Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.

Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC.

BMC Cancer. 2007 Apr 3;7:59.

17.

Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Giordano C, Catalano S, Panza S, Vizza D, Barone I, Bonofiglio D, Gelsomino L, Rizza P, Fuqua SA, Andò S.

Oncogene. 2011 Sep 29;30(39):4129-40. doi: 10.1038/onc.2011.124. Epub 2011 Apr 18.

18.

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA.

Endocr Relat Cancer. 2008 Dec;15(4):985-1002. doi: 10.1677/ERC-07-0240. Epub 2008 Sep 29.

19.

Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells.

Radde BN, Ivanova MM, Mai HX, Alizadeh-Rad N, Piell K, Van Hoose P, Cole MP, Muluhngwi P, Kalbfleisch TS, Rouchka EC, Hill BG, Klinge CM.

Exp Cell Res. 2016 Sep 10;347(1):222-31. doi: 10.1016/j.yexcr.2016.08.006. Epub 2016 Aug 8.

20.

Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.

Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, Geng M, Shen K.

Molecules. 2013 Jan 8;18(1):701-20. doi: 10.3390/molecules18010701.

Supplemental Content

Support Center